Bjerre

About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 112 blog entries.

BioCryst Reports First Quarter 2017 Financial Results

2017-05-05T07:07:07+00:00

BioCryst Pharmaceuticals, Inc. has announced the financial results for the first quarter ended March 31, 2017. "We have completed enrollment in Part 1 and 2 of the APeX-1 Phase 2 clinical trial of BCX7353 for prevention of angioedema attacks and will report top-line data in the second quarter of 2017 as planned," said Jon P. [...]

Shire delivers strong Q1 2017 revenue growth

2017-05-02T21:42:24+00:00

Shire plc has announced the unaudited results for the three months ended March 31, 2017. Flemming Ornskov, Shire CEO, commented: "In the first quarter we delivered strong top-line growth. (...) Our priorities for the rest of 2017 remain unchanged: launching new products while driving commercial excellence, generating operational efficiencies, and advancing our pipeline of novel therapies. [...]

Raising awareness step by step on the Camino

2017-05-31T19:25:10+00:00

30 people – most of them suffering from a rare and potentially fatal disease – will meet mid-May in northern Spain in order to walk part of the legendary Camino de Santiago together. The patients all suffer from Hereditary Angioedema (HAE) and it is far from an everyday occurrence to walk the kind of mileage [...]

BioCryst Expands Development to Explore Treatment of Acute HAE Attacks

2017-04-13T00:53:58+00:00

BioCryst Pharmaceuticals, Inc. plans to explore a new oral liquid formulation of BCX7353 for the treatment of acute attacks in patients with HAE. The company has received initial regulatory approvals in Europe to initiate the ZENITH-1 exploratory clinical trial this summer. "To complement the attractive profile of our prophylactic treatment program, as evidenced by the [...]

Japan Approves Berinert for Short-Term Prophylaxis

2017-03-25T01:21:24+00:00

As of 24 March 2017, Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved an extended use of Berinert from CSL Behring, a C1-esterase inhibitor (C1-INH) concentrate, for pre-procedure prevention (short-term prophylaxis) of acute episodes of HAE . Berinert is now indicated for the treatment of acute episodes and for pre-procedure prevention (short-term prophylaxis) of acute [...]

Pivotal Phase III Data for CSL Behring’s Subcutaneous C1-Esterase Inhibitor

2017-05-31T19:25:10+00:00

New England Journal of Medicine (NEJM) has published results from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) from CSL Behring. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In [...]

Cooperation and networking among health care professionals worldwide

2017-03-22T21:45:05+00:00

From 7 to 9 March 2017, CSL Behring in Bern, Switzerland hosted the First Intercontinental Immunoglobulin and Hereditary Angioedema Academy. The conference included presentations from 13 international immunodeficiency and HAE specialists, as well as a plant tour at CSL Behring AG. During the meeting, the approximately 90 immunologists from all over the world enjoyed a [...]

Cinryze first HAE treatment approved for routine prevention in paediatrics

2017-03-16T18:21:38+00:00

The European Commission has approved a label extension granting three new indications for Cinryze (C1 inhibitor [human]) from Shire plc, broadening its use to children with HAE. Cinryze is now indicated for routine prevention of angioedema attacks in children (ages 6 years and above) with severe and recurrent attacks of HAE who are intolerant to [...]

Financial report 2016 from Pharming Group

2017-05-31T19:25:10+00:00

Pharming Group N.V. has presented its (unaudited) financial report for the full year ended 31 December 2016. Sijmen de Vries, CEO and Chairman of the Board of Management, comments: 2016 was a major year for Pharming. During the year we achieved a number of positive milestones that culminated in December in the game-changing re-acquisition of [...]

KalVista appoints Senior Vice President of Medical

2017-03-10T18:49:02+00:00

KalVista Pharmaceuticals, Inc. has appointed Andreas Maetzel, M.D., M.Sc., Ph.D, to the role of Senior Vice President, Medical. “Andreas Maetzel brings a wealth of experience in HAE and over 25 years of leadership in the pharmaceutical industry, including clinical development, medical and regulatory affairs,” said Andrew Crockett, CEO of KalVista. “I am confident that he [...]